GATA2缺陷症继发肺泡蛋白沉积症合并脾脏堪萨斯分枝杆菌感染一例并文献复习
本文总结北京大学人民医院收治的1例19岁男性GATA2缺陷症继发肺泡蛋白沉积症(PAP)合并脾脏堪萨斯分枝杆菌感染病例,并检索2010年1月1日至2025年3月31日相关文献。患者表现为反复发热7年、全血细胞减少伴单核细胞缺乏、GM-CSF抗体阴性,经肺脾病理、mNGS及基因检测确诊;文献复习发现4例GATA2缺陷症病例,其中3例继发PAP、4例合并NTM感染。
要点
- 血细胞减少、GM-CSF抗体阴性的PAP伴NTM感染患者应警惕GATA2缺陷症并行GATA2基因筛查
- GATA2缺陷症可因单核细胞、NK细胞数量与功能缺陷导致免疫功能障碍,易感染NTM并继发PAP
- 造血干细胞移植是目前唯一可能根治GATA2缺陷症的方法
核心结论
- GATA2缺陷症是由GATA2基因突变引起的罕见常染色体显性遗传病,血细胞减少、GM-CSF抗体阴性PAP伴NTM感染者应考虑本病并行GATA2基因筛查。
- 造血干细胞移植是目前唯一可能根治GATA2缺陷症的方法。
研究设计与样本
- 本文为单例病例总结联合文献复习,报道北京大学人民医院收治的1例GATA2缺陷症继发PAP合并脾脏堪萨斯分枝杆菌病患者。
- 经万方数据、中国知网和美国国家生物技术信息中心数据库检索2010年1月1日至2025年3月31日相关文献并复习。
主要发现
- 患者男,19岁,反复发热7年,外周血全血细胞减少伴单核细胞缺乏,血清GM-CSF抗体阴性。
- 胸部CT示双肺弥漫间质性改变,18F-FDG PET-CT示脾大伴脾脏多发局灶性FDG代谢增高灶,骨髓穿刺提示骨髓衰竭。
- 肺穿刺病理符合PAP,脾脏病理见肉芽肿、片状坏死,脾脏mNGS检出堪萨斯分枝杆菌,基因检测示GATA2基因(c.1128del,p.Y377fs)胚系突变。
- 抗NTM治疗后感染控制,因骨髓衰竭拟行造血干细胞移植。
- 文献检索发现4例GATA2缺陷症病例,均在骨髓增殖异常基础上,3例继发PAP,4例合并NTM感染,其中1例为肺、脾、骨髓播散性NTM感染。
关键数值与推荐
- 病例诊断依据包括:全血细胞减少伴单核细胞缺乏、GM-CSF抗体阴性、肺穿刺病理符合PAP、脾脏病理见肉芽肿及片状坏死、脾脏mNGS检出堪萨斯分枝杆菌、GATA2基因(c.1128del,p.Y377fs)胚系突变。
- 文献复习4例GATA2缺陷症病例中3例继发PAP、4例合并NTM感染、1例为肺脾骨髓播散性NTM感染。
临床怎么用
- 临床遇血细胞减少、GM-CSF抗体阴性的PAP伴NTM感染患者,应想到GATA2缺陷症可能并完善GATA2基因筛查,以早期明确诊断和建立精准干预策略。
- GATA2缺陷症患者易出现单核细胞、NK细胞等数量减少和功能缺陷,即MonoMAC综合征,抵御NTM能力降低并可继发PAP。
- 造血干细胞移植是目前唯一可能根治GATA2缺陷症的方法,骨髓衰竭患者可考虑行造血干细胞移植。
局限性
- 本文为单例病例报告联合文献复习,文献检索仅发现4例GATA2缺陷症相关病例,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To enhance the understanding of the rare disease GATA2 deficiency syndrome leading to pulmonary alveolar proteinosis (PAP) and non-tuberculous mycobacterial (NTM) disease. Methods: The clinical data of a patient with GATA2 deficiency-associated PAP and splenic M. kansasii disease admitted to Peking University People's Hospital were summarized. Relevant literature from January 1, 2010 to March 31, 2025 was retrieved and reviewed through Wanfang Data, China National Knowledge Infrastructure, and the National Center for Biotechnology Information database. Results: The patient was a 19-year-old male. The clinical manifestations included recurrent fever for 7 years. The peripheral blood routine test showed peripheral blood pancytopenia accompanied by monocytopenia. The serum granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody was negative. Chest CT revealed diffuse interstitial lung changes, while 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) demonstrated splenomegaly with multiple focal FDG-avid lesions. Bone marrow biopsy indicated marrow failure. Histopathological examination of lung biopsy specimens was consistent with alveolar proteinosis, whereas histopathology of the spleen biopsy revealed granuloma and patellar necrosis. Metagenomic next-generation sequencing (mNGS) of the splenic specimen detected M. kansasii, and genetic testing identified a germline GATA2 mutation(c.1128del, p.Y377fs). Based on these findings, a diagnosis of GATA2 deficiency with secondary PAP and splenic M. kansasii infection was established. Following anti-NTM treatment, the patient's infection was controlled; however, hematopoietic stem cell transplantation was planned due to bone marrow failure. Literature search revealed 4 cases of GATA2 deficiency syndrome with bone marrow dysplasia. Three cases developed PAP. All 4 cases had NTM infection, including 1 case with disseminated NTM infection in the lungs, spleen, and bone marrow. GATA2 deficiency syndrome patients are prone to decreased numbers and functional defects of cells such as monocytes and NK cells, resulting in immune dysfunction and pulmonary alveolar macrophage dysfunction, reduced ability to resist NTM, leading to the patient being prone to NTM infection, namely MonoMAC syndrome, and can cause secondary PAP. Early identification and timely completion of genetic testing are beneficial for clear diagnosis and establishment of precise intervention strategies. Conclusion: GATA2 deficiency is a rare autosomal dominant genetic disorder caused by mutations in the GATA2 gene. Patients with cytopenia, GM-CSF antibody-negative PAP accompanied by NTM infection should be considered to have the possibility of this disease. Those patients should undergo GATA2 gene screening. Hematopoietic stem cell transplantation is currently the only possible method for curing GATA2 deficiency. 目的: 提高对罕见疾病GATA2缺陷症继发肺泡蛋白沉积症(PAP)合并非结核分枝杆菌(NTM)病的认识。 方法: 总结北京大学人民医院收治的1例GATA2缺陷症继发PAP合并脾脏堪萨斯分枝杆菌病患者的临床资料,并通过万方数据、中国知网、美国国家生物技术信息中心数据库检索2010年1月1日至2025年3月31日期间相关文献并进行复习。 结果: 患者男,19岁,临床表现为反复发热7年,外周血常规提示全血细胞减少、单核细胞缺乏,血清粒细胞-巨噬细胞集落刺激因子(GM-CSF)抗体阴性,胸部CT提示双肺弥漫间质性改变,18F-氟脱氧葡萄糖(FDG)PET/CT提示脾大、脾脏多发局灶性FDG代谢增高灶,骨髓穿刺提示骨髓衰竭,肺穿刺组织病理检查显示符合PAP,脾脏穿刺组织病理检查可见肉芽肿、片状坏死,脾脏穿刺组织宏基因组二代测序(mNGS)检测出堪萨斯分枝杆菌,患者基因检测提示为GATA2基因(c.1128del,p.Y377fs)突变,经验证为胚系突变。考虑诊断GATA2缺陷症继发PAP合并脾脏堪萨斯分枝杆菌病。经抗NTM治疗后,患者感染控制,因骨髓衰竭拟行造血干细胞移植。文献检索发现4例GATA2缺陷症病例,在骨髓增殖异常基础上,3例继发PAP,4例合并NTM感染、其中1例合并肺、脾、骨髓播散性NTM感染。GATA2缺陷症患者易发生单核细胞、NK细胞等细胞数量减少和功能缺陷,出现免疫功能缺陷及肺泡巨噬功能障碍,抵御NTM的能力降低,导致患者易于感染NTM,即MonoMAC综合征,并可引起继发性PAP。对之早期识别并及时完善基因检测,有利于明确诊断和建立精准干预策略。 结论: GATA2缺陷症是一种罕见的、由GATA2基因突变引起的常染色体显性遗传性疾病。临床遇到血细胞减少、GM-CSF抗体阴性的PAP伴NTM感染患者,应该想到本病的可能性,并进行GATA2基因筛查。造血干细胞移植是目前唯一可能根治GATA2缺陷症的方法。.
引用
- Gao WJ, Wan YQ, Bian WJ, et al. [A case of pulmonary alveolar proteinosis secondary to GATA2 deficiency combined with splenic M. kansasii infection and literature review]. Zhonghua Jie He He Hu Xi Za Zhi. 2025. PMID: 41362143. doi:10.3760/cma.j.cn112147-20250527-00287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。